i was recently exposed to hep c through a a recently used needle that had not even been rinsed from somebody that had hep c.. the needle entered my vein but when i realized it was not mine i removed it.. i did not inject... i am wondering if there is any cocktails to prevent the contraction of hep c ? i have heard that there is a cocktail for hiv if u can get it within 48 hrs after exposure its supposed to kill the virus.. so im asking if there is somthing similar for hep c it has only been about an hr since this happened. if any body knows of anything and if there is a certain window if there is a cocktail please get bk to me asap thanks !!
There IS a 25% chance that your own immune system will fight off the Hep C virus, if you did indeed contract it, within the first 6 months of having Hep C, refred to as the "acute" stage.
What you can do is wait 6 wks, and go get an "antibody screening test" for Hep C, this is an inexpensive (oft times free testing is available in big cities) test that will show if you have, indeed, been exposed.
If that is positive, you can take a "quantitative or qualitiative test", which would give you your "viral load" (quant) or typeof Hep C (qual), at around 5 months. If you have a viral load, that means your body hasn't fought it off by itself, and you can begin taking Interferon (and perhaps Ribavirin) BEFORE yr 6 month "window" is over with.
Treating Hep C in the acute phase makes it MUCH EASIER to get rid of...a much shorter Tx~ good luck
This is a good article from hcvadvocate.org. The risks it discusses are from accidental needlesticks, which might be less risky than yours since they would not hit a vein very frequently, but this is probably unknown.
Back to Medical Writers' Circle
Needlestick Exposure and Hepatitis C
By Nancy Reau, MD and Donald M. Jensen, MD
Hepatitis C virus (HCV) is a hepatitis virus transmitted through blood-to-blood exposure. Hepatitis C is commonly acquired through blood product transfusions (primarily before 1992), needle sharing (including acupuncture), tattooing, body-piercing, and even through sharing personal hygiene items. In as many as 10% of individuals transmission route cannot be explained.
What is my risk of acquiring hepatitis C from a needlestick?
Unlike hepatitis B virus, hepatitis C is not efficiently transmitted from a needlestick. The average rate of seroconversion (changing from hepatitis C antibody negative to hepatitis C antibody positive) after an occupational exposure to HCV positive blood is about 1.8%, but has ranged as high as 7-10% in some studies. This risk is highest with hollow-bore needles.
What can be done to prevent the transmission of hepatitis C?
There is currently no vaccine or immunoglobulin (IG) to protect against HCV transmission. Several studies evaluating the response to passive immunoglobulin found that high anti-HCV titer IG did not prevent transmission. This makes sense given that the rapid mutation rate of HCV allows the virus to escape from any protective antibody that may form during infection. Postexposure treatment with interferon, with or without ribavirin, is also confusing and controversial. At present, however, there is no recommendation for the use of antiviral therapy following needlestick exposure to an HCV-positive source.
What should I do if I’m exposed to HCV positive blood?
Currently, the best recommendation is to carefully monitor for laboratory abnormalities, signs and symptoms of acute hepatitis C infection. Acute hepatitis C is a difficult disease to study. This is due to the declining incidence of acute hepatitis C and the fact that most patients are not initially symptomatic. Given these limitations, a non-controlled study evaluating the response to a 24-week course of interferon alfa (Jaeckel et al.,: Treatment of Acute Hepatitis C with Interferon Alfa-2b. NEJM 2001;345:1452-1457) found that 98 percent of treated patients exhibited a sustained biochemical and virologic response 24 weeks after treatment of acute hepatitis C. These are exciting results, especially given that previous studies suggested that only 15-30% of individuals with acute infection recover without treatment.
Should we treat everyone with acute hepatitis C or exposure to hepatitis C? Before recommending any treatment, we should be sure that it is the best thing for the patient. Interferon is expensive and has many side effects, some of which could be life-threatening. The study was not controlled (i.e., there was not a group with acute hepatitis C that did not receive treatment). We know that 15-30% of patients exposed to hepatitis C will recover without any treatment. In addition, the patients in the study were symptomatic and often had jaundice. Previous investigations suggest that progression to chronic hepatitis C is much lower in young patients with jaundice, making it more likely that these individuals could have spontaneous clearance. The individuals in the study were not treated immediately after exposure, but rather months after they had symptoms. This would suggest that therapy could be delayed without adverse affects, allowing patients to spontaneously recover before prescribing an expensive and difficult to tolerate medication. But the number one reason that interferon therapy is not standard in acute infection is that we need more data to ensure that this is the most beneficial treatment to offer. Currently, the US public health service guidelines for management of HCV exposures include:
Baseline testing for anti-HCV and ALT activity
Follow-up testing at 4-6 months for anti-HCV and ALT activity or HCV RNA at 4-6 weeks
Exposed individuals should not donate blood, plasma, organs, tissue, or semen
Exposed person does not need to modify sexual practices or refrain from pregnancy or discontinue breast feeding
When HCV infection is confirmed early, the person should be referred for medical management to a specialist in this area
IG and anti-viral agents are not recommended
The 2002 NIH Consensus conference recommended that patients with acute hepatitis C were potential candidates for interferon therapy, but realized many questions remained unanswered, particularly: which patients with acute HCV should be treated, and when is the ideal time to start therapy?
Copyright February 2003 – Hepatitis C Support Project - All Rights Reserved. Permission to reprint is granted and encouraged with credit to the Hepatitis C Support Project.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.